RT Journal Article
SR Electronic
T1 Adherence to inhaled drugs – more than just reminders and nudging
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4697
DO 10.1183/13993003.congress-2022.4697
VO 60
IS suppl 66
A1 S Häussermann
A1 L Andersen
A1 M Frisch
YR 2022
UL http://erj.ersjournals.com/content/60/suppl_66/4697.abstract
AB Introduction: For Asthma and COPD, adherence to prescribed drugs is complex, since it means also the effective inhalation of the drug and inhalation needs to be trained well to be performed effectively.For this reason, patient tailored intervention is necessary for inhaled drugs. To address this, we use a digital therapeutics, called Kata®, to accompany patients with Asthma and COPD. The aim of the studies was to optimize the drug inhalation therapy through digital support by the help of augmented reality.Material and Methods: We have tested Kata® with respect to usability and clinical outcome.An app needs to be easy to use so most patients are capable to use it. The application needs to fit into patients’ daily life and must not add to the burden of disease. Both aspects are vital to increase adherence and empower patients.For clinical outcome, we have performed a proof-of-concept study in 8 Asthma patients, to calculate the sample size for the clinical trial.Results: The results of our usability studies were that 97% of patients in the age range of 7 to 76 years old were capable of using Kata® and 94% of patients found it helpful and were happy to use Kata®.In terms of handling errors and daily use, we could reduce overall handling errors from 2.2 to 0.1 errors per inhalation and critical errors from 0.5 to 0.0 errors per inhalation. Patients used Kata® on average 1.5 times a day and reported, that Kata® was supportive to cope with the burden of disease.Conclusion: Digital therapeutics are complex regarding usability, data capturing, drawing the right conclusion from data and communicating it to the patient and it is crucial to involve patients. The future study will show if we can reach clinical outcome improvements.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 4697.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).